| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
 |
ABSTRACT |
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The ICT Malaria P.f./P.v. immunochromatographic test (ICT test) is based on the detection of histidine-rich protein 2 (HRP-2) from P. falciparum, and a genus-specific panmalarial antigen (PMA) that is the Plasmodium aldolase1 present in all four of the Plasmodium species that can cause human malaria.2–5 In addition, Valecha and others6 have recently reported that the ICT test can detect PMA of rodent malaria species, including P. berghei, in mouse blood.
Whereas a number of studies have described the sensitivity for the detection of P. falciparum HRP-2 and the reactivity associated with its prolonged persistence after antimalarial treatment,2,7–11 available data regarding the sensitivity and the persistence of PMA reactivity have been limited.12–14 Because the reported sensitivities of the ICT PMA test for human malaria parasites are quite variable, particular concern about the usefulness of the ICT test for diagnosing P. vivax malaria has been expressed.15
The purpose of the present study was to evaluate the performance of the ICT test for detecting PMA in the blood of P. berghei-infected mice. Moreover, we examined the persistent reactivity of the ICT PMA test after antimalarial treatment using a rodent model.
|
MATERIALS AND METHODS |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Mosquitoes. The Anopleles stephensi SDA500 strain was a gift from Professor R. E. Sinden (Imperial College, London, United Kingdom). Mosquitoes were maintained in our insectary with a 5% fructose and 0.05% p-aminobenzoic acid (Nacalai Tesque, Inc., Kyoto, Japan) solution absorbed in filter paper at 26°C, a relative humidity of 50–70%, and a 14-hour light/10-hour dark cycle.
Mice. Female BALB/c and ICR mice were obtained from Japan SLC, Inc. (Shizuoka, Japan). The care and treatment of mice was approved by the Ethics Committee for Animal Experiments at Jichi Medical School.
Infection and drug treatment of mice. On day 0, mice were fed to starved female An. stephensi infected with P. berghei. Five to ten mosquitoes were allowed to feed on each mouse for three minutes without interruption.16 Two microliters of tail blood was taken every day, then 1.5 µL and 0.5 µL of the blood was used for the ICT test and a Giemsa-stained thin blood smear, respectively. In three independent experiments, slightly different regimens of drug treatment were given to the infected mice: Experiment 1: From day 7, when the parasite density reached 430,000–700,000/µL, infected mice (BALB/c) were given artemether (Kunming Pharmaceutical Factory, Yunnan, China) intramuscularly (1 mg/mL in olive oil) at a dose of 4 mg/kg once a day for five consecutive days; Experiment 2: From day 8, when the parasite density reached 210,000–280,000/µL, infected mice (ICR) were given artemether, 4 mg/kg once a day for five consecutive days; Experiment 3: From day 7, when the parasite density reached 70,000–190,000/µL, infected mice (ICR) were given artemether, 4 mg/kg once a day for four consecutive days.
Microscopic examination. Thin blood smears were prepared and stained with Giemsa. To declare a sample negative, smears were read for 300 microscopic fields (50x oil-immersion objective and a 10x ocular lens) without finding a parasite. If samples were found to be positive, the number of malaria parasites was counted per 5,000–50,000 red blood cells (RBCs) and the percent parasitemia was calculated. Density calculations were based on the approximation of 8 x 106 RBCs/µL in mouse blood at all stages of infection because in our experimental conditions, reduction of the RBC count (< 10%) observed for a short period during drug treatment does not have a serious impact on calculation of parasite density (Arai M, unpublished data).
ICT Malaria P.f./P.v. test. The ICT Malaria P.f./P.v. test kits (Lot 006530, expiration date November 2002; Binax, Inc., Portland, ME) were used according to the manufacturer’s instructions, with a modification of the sample volume. Briefly, 1.5 µL of whole blood, which is 10% of the recommended volume, was taken from a mouse and transferred to the sample pad. Buffer reagent was added to induce cell lysis and allow PMA to bind to colloidal gold-labeled antibodies. Additional buffer caused the blood and immune complex to migrate up the test strip and cross monoclonal antibody lines. Finally, more buffer was added to clear blood from the membrane and facilitate reading.
In this study, when the parasite density was above the detection threshold, P. berghei-infected mouse blood resulted in a visible PMA line on the ICT test strip. The test result was scored as - if no line was seen, ± if a faint test line was visible, + if the test line was clear but its intensity was less than that of the control line, ++ if the test line intensity was equal to that of the control line, and +++ if it was greater than the intensity of the control line.
Evaluation of the ICT test for PMA was made by comparison with microscopy used as the gold standard. The variables measured were the numbers of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN). Sensitivity was calculated as TP/(TP + FN), and specificity was calculated as TN/(TN + FP).2
Classification of increasing phase and declining phase. All data were classified into two phases according to the point during the course of infection the blood was examined. The increasing phase (IP) is defined as the period during which the number of parasites increases without influence of the drug. The declining phase (DP) is defined as the period during which the number of parasites is declining because of the drug treatment. When parasites were cleared in the blood smear, the following 48 hours were included in the DP. In treatment-failed cases, the period after 48 hours from parasite clearance was considered as the IP. When decreasing parasitemia was followed by an increase, the turning point was included in the DP, and the subsequent period was taken as the IP.
Statistical analysis. For each ICT PMA test score, the median parasite densities between the IP and DP were compared using the Mann-Whitney U test. All data were again classified by parasite densities and the sensitivities of the ICT PMA test between the IP and DP were compared using the chi-square test.
|
RESULTS |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
), complete success (Experiment 2, Figure 1B), or partial failure (Experiment 3, Figure 1C). During and after artemether treatment, no prolonged gametocytemia was observed in any experiment.
|
). After artemether treatment was started, the intensity of the ICT PMA band was reduced parallel to the parasitemia, but it remained positive after the parasitemia became negative on the blood smear.
All the test results in the mouse experiments were classified into the IP and DP, and parasite density was plotted versus ICT PMA line intensity in each phase (Figure 2). For each test score, a significant difference in the median parasite density was observed between the IP and DP. There were 17 false-negative results (positive by microscopy, but negative by ICT; parasite density range = 40–1,800/µL), all in the IP, and 8 false-positive results (negative by microscopy, but positive by ICT), all in the DP. Overall sensitivity and specificity was 81% and 76%, respectively.
|
. The sensitivity in the DP was significantly higher than that in the IP (100% versus 70%; P < 0.001). Such differences in sensitivity between the DP and IP were more apparent at lower parasite densities (100% versus 0% at <1,000/µL; P < 0.01 and 100% versus 50% at 1,000–10,000/µL; P < 0.05). In both phases, all samples with more than 10,000/µL parasites resulted in positive results. If phase was not considered, the sensitivity was 46% for parasite density <1,000/µL, 72% for 1,000–10,000/µL, and 100% for >10,000/µL.
|
|
DISCUSSION |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In the present study, the sensitivity for PMA was significantly higher in the DP than that in the IP, and all the false-positive results were observed only in the DP. Our findings in mice have been previously reported in a study of P. falciparum malaria. Tjitra and others14 demonstrated that the ICT test sensitivity for both PMA and HRP-2 was lower in recrudescent infections (comparable with the IP in mice) than in the initial clinical presentation with a similar level of parasitemia (comparable to a mixture of the IP and the DP).
One explanation of our findings is the persistence of PMA after clearance of parasitemia. This possibility is based on the findings that HRP-2 used in the ICT test for the detection of P. falciparum has been shown to persist and be detectable for up to four weeks after the parasites have been cleared by antimalarial treatment,2,7–11 resulting in high sensitivity at low parasitemia and false-positive results.17 However, the available information about PMA reactivity after drug treatment and clearance of parasitemia is relatively limited.12–14 Eisen and Saul12 demonstrated that PMA reactivity in the ICT test paralleled the decline of parasitemia of P. falciparum and P. vivax, suggesting only minor prolongation of PMA after clearance of parasitemia in the absence of gametocytes. In contrast, Tjitra and others13 reported that persistent reactivity of the ICT PMA test for P. falciparum was observed up to four weeks after treatment with chloroquine or sulfadoxine-pyrimethamine, which was probably due to post-treatment gametocytemia. These investigators also demonstrated that therapy with artesunate plus sulfadoxine-pyrimethamine was followed by rapid clearance of PMA, which paralleled the rapid clearance of P. falciparum gametocytemia. This is consistent with the findings of our present study in which no prolonged P. berghei gametocytemia was observed.
Another possible factor affecting the sensitivity of the ICT PMA test is duration of infection. Bechem and others18 suggested that the ability to accurately diagnose low parasitemia with antigen tests may depend on not only the number of parasites, but also the length of infection, i.e., the level of antigen accumulating in plasma. Tjitra and others14 also suggested that low sensitivity of the ICT test for both PMA and HRP-2 early in recrudescence is due to a shorter duration of recrudescent infection relative to the initial clinical illness. When one recognizes that duration of infection in the present study is necessarily longer in mice DP than in the IP, higher sensitivity observed in the DP may reflect accumulation of PMA during the infectious course.
The reported sensitivity of the ICT PMA test for human malaria parasites varies considerably depending on the study. Eisen and Saul12 reported that the threshold level for PMA detection was approximately 100 parasites/µL for P. falciparum and P. vivax. Iqbal and others15 demonstrated that the sensitivity was only 23% at <500 parasites/µL for P. falciparum and P. vivax. To understand this variation, we reviewed previous studies reporting sensitivities of the ICT PMA test for P. vivax (Table 2). If the patient population consisted mainly of symptomatic individuals, and those with history of recent malaria treatment were not excluded, the observed sensitivities of the ICT PMA test were relatively high.2,12,19 It is likely that a considerable number of patients in these studies were in the DP and had temporarily prolonged or accumulated PMA in plasma, which may have increased the apparent sensitivity.17 Conversely, in the studies in which patients with a recent history of malaria were excluded, or the patient population consisted mainly of asymptomatic individuals, the sensitivities for PMA were relatively low.17,20 It may be presumed that most of the patients in these studies were in the IP, and the observed sensitivity reflected the true sensitivity of the ICT test. It should be emphasized that in clinical situations, the patient population would be a mixture of individuals in either the IP or the DP. Moreover, the lower sensitivity of the ICT PMA test in a study of febrile returned travelers21 likely reflects the short duration of infection in non-immune travelers relative to residents of endemic areas.13,14 In endemic areas, a degree of immunity results in higher fever thresholds and allows for greater chronicity before seeking treatment,2,22 which likely contributes to a higher sensitivity for antigen tests. We therefore hypothesize that the detection sensitivity of the ICT PMA test may depend on both the infection phase (IP or DP) and the duration of infection.
|
In conclusion, ICT kit users should be aware that 1) antimalarial treatment results in temporarily prolonged circulation of PMA, which causes inappropriately high sensitivity and false-positive results, 2) the true sensitivity for PMA may be approximately 2,000 parasite/µL, and 3) individual history of recent fever, duration of illness, and drug treatment must be carefully considered for the interpretation of the test results.
Received July 17, 2003. Accepted for publication October 7, 2003.
Acknowledgments: We thank Midori Sato and Kazuko Kosuge for technical assistance.
Financial support: This study was supported by a Grant-in-Aid for Scientific Research B (14406026) from the Japan Society for Promotion of Science, and by the Japanese Ministry of Health, Labor and Welfare (13C-5).
Authors’ address: Meiji Arai, Akira Ishii, and Hiroyuki Matsuoka, Department of Medical Zoology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan.
Reprint requests: Meiji Arai, Department of Medical Zoology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan, Telephone: 81-285-58-7339, Fax: 81-285-44-6489, E-mail: marai{at}ms.jichi.ac.jp.
|
REFERENCES |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) and declining phase (•), according to the point during the course of infection the blood was examined (see Materials and Methods for the classification criteria). Horizontal lines indicate medians. *P < 0.05 and **P < 0.01 indicate significant differences from corresponding results in the declining phase by the Mann-Whitney U test.